苯甲醇,2-羟基-6-(1-戊烯基)- | 193278-35-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苯甲醇,2-羟基-6-(1-戊烯基)-
• 英文名称: 2-(Hydroxymethyl)-3-(pent-1-en-1-yl)phenol
• 英文别名: 2-(hydroxymethyl)-3-pent-1-enylphenol
• CAS: 193278-35-2
• 化学式: C₁₂H₁₆O₂
• 分子量: 192.25
• InChiKey: DBQOSYCAGOGELV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Receptor and Antigen Targeted Prodrug
  申请人：Kratz Felix

  公开号：US20100111866A1

  公开（公告）日：2010-05-06

  The present invention relates to a prodrug which comprises at least one pharmaceutically and/or diagnostically active compound bound by a cleavable linker, a receptor and/or antigen targeting moiety and a protein-binding moiety which is capable of binding to a carrier molecule.

  本发明涉及一种前药，其包含至少一种药用和/或诊断活性化合物，通过可断裂的连接剂，一个受体和/或抗原靶向基团和一个能够结合载体分子的蛋白质结合基团。
• Composition for inducing immunotolerance
  申请人：Universiteit Utrecht Holding B.V.

  公开号：EP1772152A2

  公开（公告）日：2007-04-11

  The present invention provides methods of treating allergic disorders and compositions for use therein. The methods comprise administering an allergen and one or more medicaments. These medicaments are compounds that inhibit the transcription of genes involved in the initiation of innate and specific immunity, thereby promoting the development of tolerance to these allergens, through inhibition of the NF-κB and/or the MAPK/AP-1 signal transduction pathway(s). In another embodiment, the use of DNA vaccines is disclosed that incorporate a gene encoding one or more allergen sequences or fragments thereof, in combination with genes encoding proteins that inhibit the activation of the NF-κB and/or the MAPK/AP-1 pathway or in combination with small interfering RNA sequences or anti-sense sequences that inhibit the expression of NF-κB and/or AP-1 proteins.

  本发明提供了治疗过敏性疾病的方法及其使用的组合物。这些方法包括施用过敏原和一种或多种药物。这些药物是通过抑制NF-κB和/或MAPK/AP-1信号转导途径，抑制参与先天性免疫和特异性免疫启动的基因转录，从而促进对这些过敏原的耐受性发展的化合物。在另一个实施方案中，公开了 DNA 疫苗的使用，该疫苗包含编码一种或多种过敏原序列或其片段的基因，与编码抑制 NF-κB 和/或 MAPK/AP-1 通路活化的蛋白质的基因相结合，或与抑制 NF-κB 和/或 AP-1 蛋白表达的小干扰 RNA 序列或反义序列相结合。
• Clonidine to treat pain locally
  申请人：Medtronic, Inc.

  公开号：EP2363122A1

  公开（公告）日：2011-09-07

  The present invention is directed to systems and methods for contributing to the local treatment of pain. More specifically, the present invention is directed to the use of one or more NFKB inhibiting compounds, particularly clonidine, in the manufacture of a medicament for the treatment of pain wherein said medicament is for local administration to a patient in need thereof.

  本发明涉及有助于局部治疗疼痛的系统和方法。更具体地说，本发明涉及将一种或多种 NFKB 抑制化合物，特别是氯硝柳胺，用于制造治疗疼痛的药物，其中所述药物用于对有需要的患者进行局部给药。
• Combination of drugs with protein-binding prodrugs
  申请人：KTB Tumorforschungsgesellschaft mbH

  公开号：EP2382993A1

  公开（公告）日：2011-11-02

  The present invention relates to a composition and a combination comprising at least one first drug and at least one protein-binding prodrug, wherein the protein-binding prodrug comprises a protein-binding group, a second drug, and a linker that can be cleaved hydrolytically, enzymatically, or in a pH-dependent manner in the body, as well as to a kit and a pharmaceutical composition comprising said composition or combination.

  本发明涉及一种由至少一种第一药物和至少一种蛋白质结合原药组成的组合物和组合剂，其中蛋白质结合原药包括蛋白质结合基团、第二药物和可在体内以水解、酶解或随 pH 值变化的方式裂解的连接体，还涉及一种包含所述组合物或组合剂的试剂盒和药物组合物。
• Receptor And Antigen Targeted Prodrug
  申请人：KTB Tumorforschungsgesellschaft mbH

  公开号：EP2604284A1

  公开（公告）日：2013-06-19

  The present invention relates to a prodrug which comprises at least one pharmaceutically and/or diagnostically active compound bound by a cleavable linker, a receptor and/or antigen targeting moiety comprising a folic acid derivative and a protein-binding moiety which is capable of binding to a carrier molecule.

  本发明涉及一种原药，它包括至少一种由可裂解连接体结合的药用和/或诊断活性化合物、由叶酸衍生物组成的受体和/或抗原靶向分子以及能够与载体分子结合的蛋白质结合分子。